5azadC treatment upregulates miR-375 level and represses HPV16 E6 expression

Adrien Morel, Aurélie Baguet, Jérôme Perrard, Caroline Demeret, Elise Jacquin, David Guenat, Christiane Mougin, Jean Luc Prétet

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

High-risk human papillomaviruses are the etiological agents of cervical cancer and HPV16 is the most oncogenic genotype. Immortalization and transformation of infected cells requires the overexpression of the two viral oncoproteins E6 and E7 following HPV DNA integration into the host cell genome. Integration often leads to the loss of the E2 open reading frame and the corresponding protein can no longer act as a transcriptional repressor on p97 promoter. Recently, it has been proposed that long control region methylation also contributes to the regulation of E6/E7 expression. To determine which epigenetic mechanism is involved in HPV16 early gene regulation, 5-aza-2'-deoxycytidine was used to demethylate Ca Ski and SiHa cell DNA. Decreased expression of E6 mRNA and protein levels was observed in both cell lines in an E2- independent manner. E6 repression was accompanied by neither a modification of the main cellular transcription factor expression involved in long control region regulation, nor by a modification of the E6 mRNA splicing pattern. In contrast, a pronounced upregulation of miR-375, known to destabilize HPV16 early viral mRNA, was observed. Finally, the use of miR-375 inhibitor definitively proved the involvement of miR-375 in E6 repression. These results highlight that cellular DNA methylation modulates HPV16 early gene expression and support a role for epigenetic events in high-risk HPV associated-carcinogenesis.

Original languageEnglish (US)
Pages (from-to)46163-46176
Number of pages14
JournalOncotarget
Volume8
Issue number28
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Dive into the research topics of '5azadC treatment upregulates miR-375 level and represses HPV16 E6 expression'. Together they form a unique fingerprint.

  • Cite this

    Morel, A., Baguet, A., Perrard, J., Demeret, C., Jacquin, E., Guenat, D., Mougin, C., & Prétet, J. L. (2017). 5azadC treatment upregulates miR-375 level and represses HPV16 E6 expression. Oncotarget, 8(28), 46163-46176. https://doi.org/10.18632/oncotarget.17575